Andreas Ritzén
Andreas Ritzén has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Alison M. Paterson
Monte Rosa Therapeutics Inc, Boston, MA, USA
2 shared publicationsAnders Jerre
2 shared publicationsArnaud Osmont
Monte Rosa Therapeutics Inc, Boston, MA, USA
2 shared publicationsAurélie Dubois
Monte Rosa Therapeutics Inc, Boston, MA, USA
2 shared publicationsCamille Staehly
Monte Rosa Therapeutics Inc, Boston, MA, USA
2 shared publicationsDaniel T. Lam
Monte Rosa Therapeutics Inc, Boston, MA, USA
2 shared publications
Latest Publications
- Top Cited Papers
- 3 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6755) , eadt6736
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
The CRL4 CRBN E3 ubiquitin ligase is the target of molecular glue degrader compounds that reprogram ligase specificity to induce the degradation of clinically relevant neosubstrate proteins. Known cereblon (CRBN) neosubstrates share a generalizable β-hairpin G-loop recognition motif that allows for the systematic exploration of the CRBN target space. Computational mining approaches using structure- and surface-based matchmaking algorithms predict more than 1600 CRBN-compatible G-loop proteins across the human proteome, including the newly discovered helical G-loop motif, and identify the noncanonical neosubstrate binding mode of VAV1 that engages CRBN through a molecular surface mimicry mechanism. This work broadens the CRBN target space, redefines rules for neosubstrate recognition, and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
- 3 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6755) , eadt6736
Top Cited PapersMining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
The CRL4 CRBN E3 ubiquitin ligase is the target of molecular glue degrader compounds that reprogram ligase specificity to induce the degradation of clinically relevant neosubstrate proteins. Known cereblon (CRBN) neosubstrates share a generalizable β-hairpin G-loop recognition motif that allows for the systematic exploration of the CRBN target space. Computational mining approaches using structure- and surface-based matchmaking algorithms predict more than 1600 CRBN-compatible G-loop proteins across the human proteome, including the newly discovered helical G-loop motif, and identify the noncanonical neosubstrate binding mode of VAV1 that engages CRBN through a molecular surface mimicry mechanism. This work broadens the CRBN target space, redefines rules for neosubstrate recognition, and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
- Open Access
Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition
The CRL4 CRBN ubiquitin ligase is leveraged by molecular glue degraders, small molecules that reprogram ligase specificity to induce degradation of clinically relevant neosubstrate proteins. Known CRBN neosubstrates share a generalizable β-hairpin G-loop recognition motif, yet systematic exploration of the CRBN target landscape is still pending. Through computational mining of the human proteome using structure-based approaches, we predict over 1,400 CRBN-compatible β-hairpin G-loop proteins across diverse target classes, identify novel mechanisms of neosubstrate recognition through structurally differentiated helical motifs and molecular surface mimicry, and validate 22 representative neosubstrates with clinical implications. This work broadens the CRBN target space, redefines rules for neosubstrate recognition and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
Open AccessMining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition
The CRL4 CRBN ubiquitin ligase is leveraged by molecular glue degraders, small molecules that reprogram ligase specificity to induce degradation of clinically relevant neosubstrate proteins. Known CRBN neosubstrates share a generalizable β-hairpin G-loop recognition motif, yet systematic exploration of the CRBN target landscape is still pending. Through computational mining of the human proteome using structure-based approaches, we predict over 1,400 CRBN-compatible β-hairpin G-loop proteins across diverse target classes, identify novel mechanisms of neosubstrate recognition through structurally differentiated helical motifs and molecular surface mimicry, and validate 22 representative neosubstrates with clinical implications. This work broadens the CRBN target space, redefines rules for neosubstrate recognition and establishes a platform for the elimination of challenging drug targets by repurposing CRL4 CRBN through next-generation molecular glue degraders.
- 8 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (17) , 2669-2685
Prediction of Chameleonic Efficiency
Chameleonic properties, i. e., the capacity of a molecule to hide polarity in non‐polar environments and expose it in water, help achieving sufficient permeability and solubility for drug molecules with high MW. We present models of experimental measures of polarity for a set of 24 FDA approved drugs (MW 405‐1113) and one PROTAC (MW 1034). Conformational ensembles in aqueous and non‐polar environments were generated using molecular dynamics. A linear regression model that predicts chromatographic apparent polarity (EPSA) with a mean unsigned error of 10 Å2 was derived based on separate terms for donor, acceptor, and total molecular SASA. A good correlation (R2=0.92) with an experimental measure of hydrogen bond donor potential, Δlog Poct‐tol, was found for the mean hydrogen bond donor SASA of the conformational ensemble scaled with Abraham's A hydrogen bond acidity. Two quantitative measures of chameleonic behaviour, the chameleonic efficiency indices, are introduced. We envision that the methods presented herein will be useful to triage designed molecules and prioritize those with the best chance of achieving acceptable permeability and solubility.
- 8 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (17) , 2669-2685
Prediction of Chameleonic Efficiency
Chameleonic properties, i. e., the capacity of a molecule to hide polarity in non‐polar environments and expose it in water, help achieving sufficient permeability and solubility for drug molecules with high MW. We present models of experimental measures of polarity for a set of 24 FDA approved drugs (MW 405‐1113) and one PROTAC (MW 1034). Conformational ensembles in aqueous and non‐polar environments were generated using molecular dynamics. A linear regression model that predicts chromatographic apparent polarity (EPSA) with a mean unsigned error of 10 Å2 was derived based on separate terms for donor, acceptor, and total molecular SASA. A good correlation (R2=0.92) with an experimental measure of hydrogen bond donor potential, Δlog Poct‐tol, was found for the mean hydrogen bond donor SASA of the conformational ensemble scaled with Abraham's A hydrogen bond acidity. Two quantitative measures of chameleonic behaviour, the chameleonic efficiency indices, are introduced. We envision that the methods presented herein will be useful to triage designed molecules and prioritize those with the best chance of achieving acceptable permeability and solubility.
- Open Access
- 10 June 2021
- Published by American Chemical Society (ACS) in ChemRxiv
Prediction of Chameleonic Efficiency
Prediction of chameleonic properties from environment-dependent conformational ensembles generated by molecular dynamics in explicit solvent is presented. This methodology yields predictive models of overall polarity (experimentally determined EPSA) and hydrogen bond donor exposure (experimentally measured delta log Poct-tol) for 24 FDA-approved drug molecules. Two quantitative indices of chameleonic efficiency are introduced to aid drug designers striving to combine sufficient permeability and solubility.
- 10 June 2021
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPrediction of Chameleonic Efficiency
Prediction of chameleonic properties from environment-dependent conformational ensembles generated by molecular dynamics in explicit solvent is presented. This methodology yields predictive models of overall polarity (experimentally determined EPSA) and hydrogen bond donor exposure (experimentally measured delta log Poct-tol) for 24 FDA-approved drug molecules. Two quantitative indices of chameleonic efficiency are introduced to aid drug designers striving to combine sufficient permeability and solubility.
- 28 May 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (13) , 7008-7032
Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity
Herein we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.
- 28 May 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (13) , 7008-7032
Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity
Herein we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.
- Open Access
- 19 April 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (6) , 641-646
Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors
Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.
- 19 April 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (6) , 641-646
Open AccessFragment-Based Discovery of 6-Arylindazole JAK Inhibitors
Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.
- 28 May 2013
- Published by Wiley in Chemistry – A European Journal
- Vol. 19 (28) , 9343-9350
Multistep Continuous‐Flow Synthesis in Medicinal Chemistry: Discovery and Preliminary Structure–Activity Relationships of CCR8 Ligands
A three‐step continuous‐flow synthesis system and its application to the assembly of a new series of chemokine receptor ligands directly from commercial building blocks is reported. No scavenger columns or solvent switches are necessary to recover the desired test compounds, which were obtained in overall yields of 49–94 %. The system is modular and flexible, and the individual steps of the sequence can be interchanged with similar outcome, extending the scope of the chemistry. Biological evaluation confirmed activity on the chemokine CCR8 receptor and provided initial structure–activity‐relationship (SAR) information for this new ligand series, with the most potent member displaying full agonist activity with single‐digit nanomolar potency. To the best of our knowledge, this represents the first published example of efficient use of multistep flow synthesis combined with biological testing and SAR studies in medicinal chemistry.
- 28 May 2013
- Published by Wiley in Chemistry – A European Journal
- Vol. 19 (28) , 9343-9350
Multistep Continuous‐Flow Synthesis in Medicinal Chemistry: Discovery and Preliminary Structure–Activity Relationships of CCR8 Ligands
A three‐step continuous‐flow synthesis system and its application to the assembly of a new series of chemokine receptor ligands directly from commercial building blocks is reported. No scavenger columns or solvent switches are necessary to recover the desired test compounds, which were obtained in overall yields of 49–94 %. The system is modular and flexible, and the individual steps of the sequence can be interchanged with similar outcome, extending the scope of the chemistry. Biological evaluation confirmed activity on the chemokine CCR8 receptor and provided initial structure–activity‐relationship (SAR) information for this new ligand series, with the most potent member displaying full agonist activity with single‐digit nanomolar potency. To the best of our knowledge, this represents the first published example of efficient use of multistep flow synthesis combined with biological testing and SAR studies in medicinal chemistry.
- 5 January 2001
- Published by Wiley in ChemBioChem
- Vol. 2 (1) , 69-75
Synthesis and Biological Evaluation of 12,13-Cyclopropyl and 12,13-Cyclobutyl Epothilones
- 5 January 2001
- Published by Wiley in ChemBioChem
- Vol. 2 (1) , 69-75
Synthesis and Biological Evaluation of 12,13-Cyclopropyl and 12,13-Cyclobutyl Epothilones